# A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors

> **NCT06150885** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ever Supreme Bio Technology Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** HLA-G-CAR.BiTE allogeneic γδ T cells

## Key facts

- **NCT ID:** NCT06150885
- **Lead sponsor:** Ever Supreme Bio Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06150885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06150885, "A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06150885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*